Suppr超能文献

UDP-N-乙酰-D-半乳糖胺:多肽N-乙酰半乳糖胺基转移酶6(ppGalNAc-T6)mRNA作为检测骨髓播散性乳腺癌细胞的潜在新标志物。

UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (ppGalNAc-T6) mRNA as a potential new marker for detection of bone marrow-disseminated breast cancer cells.

作者信息

Freire Teresa, Berois Nora, Sóñora Cecilia, Varangot Mario, Barrios Enrique, Osinaga Eduardo

机构信息

Laboratorio de Oncología Básica y Biología Molecular, Dpto. de Bioquímica, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay.

出版信息

Int J Cancer. 2006 Sep 15;119(6):1383-8. doi: 10.1002/ijc.21959.

Abstract

The evaluation of disseminated epithelial tumor cells in patients with early stages of breast cancer has generated considerable interest because of its potential association with poor clinical outcome. Considering that O-glycosylation pathways are frequently altered in breast cancer, we performed this work to evaluate the potential usefulness of UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferases (ppGalNAc-Ts) (a family of glycosyltransferases which catalyze the first key step of mucin-type O-glycosylation) to detect disseminated cells in bone marrow samples from patients with operable breast cancer. Using RT-PCR assays, we studied the gene expression of 9 enzymes (ppGalNAc-T1-T9). Among the ppGalNAc-Ts expressed by breast tumors (-T1, -T2, -T3, -T6 and -T7), the best specificity (negative results on all PBMN cell samples from healthy donors) was shown for ppGalNAc-T6. Thus, we selected this enzyme as a target gene for further evaluation. ppGalNAc-T6 mRNA was found in 22/25 (88%) breast cancer samples, in all 3 human breast cancer cell lines evaluated (MCF-7, ZR75-1 and T47D), in 1/30 (3%) PBMN cells and 0/19 bone marrow samples obtained from patients without cancer. Using this method, 22/61 (36%) patients with breast cancer, who underwent curative surgery, showed positive ppGalNAc-T6 mRNA in bone marrow aspirates obtained prior to surgery, including 11/34 patients with stage-I or -II, without histopathological lymph node involvement. In a preliminary follow-up evaluation, 19/61 patients experienced recurrence of the disease. ppGalNAc-T6 was positive in 11/19 (57.9%) of these patients. Interestingly, in the group of patients without lymph node involvement, disease recurrence was observed in 54.5% of patients who showed ppGalNAc-T6 mRNA-positive bone marrow aspirates and only in 4.3% of patients when ppGalNAc-T6 was negative (p = 0.014). These results indicate that ppGalNAc-T6 mRNA could be a specific marker applicable to the molecular diagnosis of breast cancer cells dissemination.

摘要

由于其与不良临床结局的潜在关联,对早期乳腺癌患者中播散性上皮肿瘤细胞的评估引起了广泛关注。鉴于O-糖基化途径在乳腺癌中经常发生改变,我们开展了这项工作,以评估UDP-N-乙酰-D-半乳糖胺:多肽N-乙酰半乳糖胺基转移酶(ppGalNAc-Ts,一类催化粘蛋白型O-糖基化第一步关键反应的糖基转移酶家族)在检测可手术乳腺癌患者骨髓样本中播散细胞方面的潜在效用。我们使用逆转录聚合酶链反应(RT-PCR)分析方法,研究了9种酶(ppGalNAc-T1-T9)的基因表达。在乳腺癌表达的ppGalNAc-Ts中(-T1、-T2、-T3、-T6和-T7),ppGalNAc-T6表现出最佳的特异性(在所有健康供体的外周血单核细胞样本中均为阴性结果)。因此,我们选择该酶作为进一步评估的靶基因。在25份乳腺癌样本中的22份(88%)、所有评估的3种人乳腺癌细胞系(MCF-7、ZR75-1和T47D)、30份外周血单核细胞样本中的1份(3%)以及19份来自无癌患者的骨髓样本中的0份中发现了ppGalNAc-T6 mRNA。使用该方法,61例接受根治性手术的乳腺癌患者中有22例(36%)在术前获得的骨髓抽吸物中显示ppGalNAc-T6 mRNA阳性,其中包括34例I期或II期、无组织病理学淋巴结受累的患者中的11例。在初步的随访评估中,61例患者中有19例疾病复发。这些复发患者中有11例(57.9%)的ppGalNAc-T6呈阳性。有趣地是,在无淋巴结受累的患者组中,ppGalNAc-T6 mRNA阳性骨髓抽吸物的患者中有54.5%出现疾病复发,而ppGalNAc-T6阴性的患者中只有4.3%复发(p = 0.014)。这些结果表明,ppGalNAc-T6 mRNA可能是一种适用于乳腺癌细胞播散分子诊断的特异性标志物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验